Enerzair Breezhaler 150/50/160 μg
Enerzair Breezhaler 150/50/160 μg is a medicine authorised by Swissmedic under authorisation number 67596. The authorisation holder is Novartis Pharma Schweiz AG. The medicinal product code is Synthetic medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 24 September 2020 and the authorisation is valid without a time limit. ATC code R03AL12 places the medicine in the group Drugs for obstructive airway diseases.
| Authorisation number | 67596 |
|---|---|
| Name | Enerzair Breezhaler 150/50/160 μg |
| Full name | Enerzair Breezhaler 150/50/160 μg, Hartkapsel mit Pulver zur Inhalation |
| Authorisation holder | Novartis Pharma Schweiz AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | B · Prescription only |
| ATC code | R03AL12 |
| First authorisation | 24 September 2020 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 2 | Enerzair Breezhaler 150/50/160 μg, Hartkapsel mit Pulver zur Inhalation | B | 24 September 2020 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 4 | 30 | Kapsel(n) | R03AL12 | 03.04.5. | B |
| 5 | 90 | Kapsel(n) | R03AL12 | 03.04.5. | B |
Scroll the table sideways
Other medicines from this authorisation holder
Frequently asked questions
Is Enerzair Breezhaler 150/50/160 μg authorised in Switzerland?
Yes. Enerzair Breezhaler 150/50/160 μg is authorised by Swissmedic under authorisation number 67596, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Enerzair Breezhaler 150/50/160 μg have?
Enerzair Breezhaler 150/50/160 μg is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Enerzair Breezhaler 150/50/160 μg?
The authorisation holder is Novartis Pharma Schweiz AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.